Josh Mandel-Brehm insider trades

Open-market stock purchases and sales by Josh Mandel-Brehm, Director at ProMIS Neurosciences Inc, from SEC Form 4 filings since Oct 3, 2024.

Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +130%.

Recent trades

DateStockTradeValue
May 20, 2026PMN ProMIS Neurosciences IncBought (not open market)—
May 20, 2026PMN ProMIS Neurosciences IncBought (not open market)—
Apr 1, 2026CAMP Camp4 Therapeutics CorpBought (not open market)—
Dec 11, 2025CAMP Camp4 Therapeutics CorpBought (not open market)—

Companies traded

  • PMN ProMIS Neurosciences Inc: other filings, last May 20, 2026
  • CAMP Camp4 Therapeutics Corp: 1 buy, last Apr 1, 2026

Get free alerts when Josh Mandel-Brehm files a new trade →